The VEGF-targeted therapy outperformed EGFR-targeted therapy: 32 (95 %CI: 21-Not reached) vs. 15 (95 %CI: 11-40) months (p=0.042).<h4>Conclusions</h4>Preoperative chemotherapy with targeted antibodies improves overall survival in CRC-PM in patients that are not candidates for upfront CRS and HIPEC. The gene discussed is EGFR; the disease is colorectal carcinoma.